AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
Zacks.com on MSN1d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...
Analyst Graig Suvannavejh of Mizuho Securities maintained a Buy rating on Alector (ALEC – Research Report), with a price target of $9.00.
Sen. William Parkinson shakes hands with John Querry, a maintenance supervisor with the Inalåhan Mayor’s Office, after senators voted to amend a supplemental budget bill to appropriate $4.5 ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...
With emraclidine now unlikely to reach the market, AbbVie will be hoping that Cerevel’s other assets fare better. One asset, ...
AbbVie completed the acquisition of Cerevel Therapeutics in the third quarter, which will expand its neuroscience portfolio ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback